Comprehensive Stock Comparison
Compare The Pennant Group, Inc. (PNTG) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs PNTG's 36.3% |
| Quality / Margins | PNTG | 3.1% net margin vs AGIO's -9.0% |
| Stability / Safety | PNTG | Beta 0.54 vs AGIO's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PNTG | +48.0% vs AGIO's -14.9% |
| Efficiency (ROA) | PNTG | 3.1% ROA vs AGIO's -29.0%, ROIC 5.7% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
The Pennant Group operates a network of home health, hospice, and senior living facilities across the United States. It generates revenue primarily from Medicare and Medicaid reimbursements for home health and hospice services—roughly 70% of total revenue—with the remainder coming from private pay and insurance for senior living communities. The company's decentralized operating model—which grants local leaders significant autonomy—creates a competitive advantage through better community integration and operational efficiency compared to more centralized healthcare providers.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PNTG leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
PNTG is the larger business by revenue, generating $948M annually — 21.2x AGIO's $45M. PNTG is the more profitable business, keeping 3.1% of every revenue dollar as net income compared to AGIO's -9.0%. On growth, PNTG holds the edge at +53.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $948M | $45M |
| EBITDAEarnings before interest/tax | $60M | -$470M |
| Net IncomeAfter-tax profit | $30M | -$401M |
| Free Cash FlowCash after capex | $33M | -$414M |
| Gross MarginGross profit ÷ Revenue | +11.2% | +84.4% |
| Operating MarginEBIT ÷ Revenue | +5.5% | -10.6% |
| Net MarginNet income ÷ Revenue | +3.1% | -9.0% |
| FCF MarginFCF ÷ Revenue | +3.5% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +53.2% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | -111.0% |
Valuation Metrics
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $1.2B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 40.13x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.82x | — |
| PEG RatioP/E ÷ EPS growth rate | 3.99x | — |
| EV / EBITDAEnterprise value multiple | 26.68x | — |
| Price / SalesMarket cap ÷ Revenue | 1.24x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 3.18x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 24.35x | — |
Profitability & Efficiency
PNTG delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-31 for AGIO. AGIO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PNTG's 1.21x.
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | +7.9% | -31.2% |
| ROA (TTM)Return on assets | +3.1% | -29.0% |
| ROICReturn on invested capital | +5.7% | -26.6% |
| ROCEReturn on capital employed | +7.4% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 1.21x | 0.03x |
| Net DebtTotal debt minus cash | $436M | -$49M |
| Cash & Equiv.Liquid assets | $17M | $89M |
| Total DebtShort + long-term debt | $453M | $40M |
| Interest CoverageEBIT ÷ Interest expense | 202.23x | — |
Total Returns (with DRIP)
A $10,000 investment in PNTG five years ago would be worth $6,436 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, PNTG leads with a +48.0% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors PNTG at 30.9% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +21.1% | +11.2% |
| 1-Year ReturnPast 12 months | +48.0% | -14.9% |
| 3-Year ReturnCumulative with dividends | +124.4% | +19.4% |
| 5-Year ReturnCumulative with dividends | -35.6% | -36.4% |
| 10-Year ReturnCumulative with dividends | +123.4% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +30.9% | +6.1% |
Risk & Volatility
PNTG is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PNTG currently trades 96.3% from its 52-week high vs AGIO's 65.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.91x |
| 52-Week HighHighest price in past year | $35.00 | $46.00 |
| 52-Week LowLowest price in past year | $21.18 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 226K | 948K |
Analyst Outlook
Wall Street rates PNTG as "Buy" and AGIO as "Buy". Consensus price targets imply 37.3% upside for AGIO (target: $42) vs 15.7% for PNTG (target: $39).
| Metric | PNTGThe Pennant Group… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $39.00 | $41.50 |
| # AnalystsCovering analysts | 7 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 100 | 104.89 | +4.9% |
| Agios Pharmaceutica… (AGIO) | 100 | 57.07 | -42.9% |
The Pennant Group, … (PNTG) returned -36% over 5 years vs Agios Pharmaceutica… (AGIO)'s -36%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | $251M | $948M | +277.6% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 3.9% | 3.1% | -20.6% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4P/E Ratio History — 7 Years
| Stock | 2019 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 384.5 | 33.5 | -91.3% |
The Pennant Group, Inc. has traded in a 32x–385x P/E range over 7 years; current trailing P/E is ~40x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 0.35 | 0.84 | +140.0% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 6Free Cash Flow — 5 Years
The Pennant Group, Inc. generated $48M FCF in 2025 (+297% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
PNTG vs AGIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PNTG or AGIO a better buy right now?
The Pennant Group, Inc. (PNTG) offers the better valuation at 40.1x trailing P/E (25.8x forward), making it the more compelling value choice. Analysts rate The Pennant Group, Inc. (PNTG) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PNTG or AGIO?
Over the past 5 years, The Pennant Group, Inc. (PNTG) delivered a total return of -35.6%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in PNTG five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PNTG returned +123.4% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PNTG or AGIO?
By beta (market sensitivity over 5 years), The Pennant Group, Inc. (PNTG) is the lower-risk stock at 0.54β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 67% more volatile than PNTG relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 121% for The Pennant Group, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — PNTG or AGIO?
The Pennant Group, Inc. (PNTG) is the more profitable company, earning 3.1% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 3.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PNTG leads at 5.5% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is PNTG or AGIO more undervalued right now?
Analyst consensus price targets imply the most upside for AGIO: 37.3% to $41.50.
06Which pays a better dividend — PNTG or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PNTG or AGIO better for a retirement portfolio?
For long-horizon retirement investors, The Pennant Group, Inc. (PNTG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.54), +123.4% 10Y return). Both have compounded well over 10 years (PNTG: +123.4%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PNTG and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.